Needham Maintains Buy on Cellebrite DI, Lowers Price Target to $12.5
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Needham analyst Mike Cikos maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and lowers the price target from $15 to $12.5.
Needham analyst Mike Cikos maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and lowers the price target from $15 to $12.5.